

IN THE SPECIFICATION:

Please insert the following paragraph after the title of the invention and prior to the FIELD OF THE INVENTION:

**--CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a continuation of U.S. Patent Application Serial No. 08/536,891, filed September 29, 1995, now U.S. Patent No. 6,033,907, which is a continuation-in-part of International Application No. PCT/US95/03817 designating the United States, filed March 27, 1995, which is a continuation-in-part of U.S. Patent Application No. 08/218,355, filed March 25, 1994, now U.S. Patent No. 5,686,278.--

IN THE CLAIMS:

Please amend claims 24, 32, 44, 52, 62, and 84 as follows;

24. (Amended) An improved method for cellular grafting, comprising the steps of:

obtaining viable hematopoietic cells from a mammalian donor;  
infecting the viable hematopoietic cells with a replication-defective recombinant retrovirus vector containing exogenous DNA to produce transduced viable hematopoietic cells, the infecting being in the presence of an immobilized amount of fibronectin and/or a fragment thereof effective to increase the efficiency of cellular transduction by the retrovirus vector; and

introducing the transduced viable hematopoietic cells into a mammalian recipient as a cellular graft.

32. (Amended) A method for increasing the frequency of transduction of hematopoietic cells *in vitro* by a replication-defective recombinant retrovirus vector, comprising infecting a population of viable hematopoietic cells enriched in hematopoietic stem cells with a replication-defective recombinant retrovirus vector in